MAGEA6 and lung carcinoma: Since PDAC patients often present with late-stage disease and a low 5 year survival rate, we reasoned that lung cancer is a better option for evaluating the impact of MAGEA6 on different stages of cancer development (initiation and progression) because (1) a large number of patients with lung cancer showed high MAGEA6 expression and mutation events, and (2) approximately one-third of MAGEA6 mutation events (6/17) found in the ICGC lung cancer database displayed reduced protein expression (Figure 6—figure supplement 3).